| Q35185203 | Artificial Oxygen Carrying Blood Substitutes |
| Q70425658 | Artificial blood |
| Q36990411 | Blood substitutes: evolution from noncarrying to oxygen- and gas-carrying fluids. |
| Q35805601 | Current status of erythrocyte substitutes |
| Q70283626 | Effect of a perfluorochemical emulsion on the development of artificial lung metastases in mice |
| Q50758572 | Effect of two perfluorocarbon emulsions on reperfusion injury after coronary artery occlusion in rabbits. |
| Q71795097 | Effects of A 100% Perfluorooctylbromide Emulsion on Ischemia/Reperfusion Injury Following Cardioplegia |
| Q72747044 | Effects of fluorocarbons with and without oxygen supplementation on cardiac hemodynamics and energetics |
| Q40466595 | Fluorocarbon emulsions |
| Q44030552 | Hemodynamic, metabolic, and morphological effects of cardiopulmonary bypass with a fluorocarbon priming solution |
| Q71688966 | In vivo coronary angioscopy |
| Q39760880 | Perfluorocarbon blood substitutes |
| Q69901454 | Placebo-controlled, double-blind study of haemodilution in peripheral arterial disease |
| Q71686471 | Red blood cell substitutes and artificial blood |
| Q50880748 | Reduction in reperfusion injury by blood-free reperfusion after experimental myocardial infarction. |
| Q93576330 | Relation between left ventricular global and regional function and extent of myocardial ischemia in the canine heart |
| Q40153173 | Review Article Blood component therapy in anaesthetic practice |
| Q74545815 | The role of oxygen in cutaneous photodynamic therapy |
| Q39239359 | U.S. Clinical Studies of the Treatment of Anemia with Fluosol-DA 20% |